## 504932109 05/25/2018

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4978855

SUBMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE:		ASSIGNMENT			
CONVEYING PARTY D	ΑΤΑ				
		Name		Execution Date	
JANSSEN INFECTIOUS	DISEAS	SES BVBA		03/05/2012	
RECEIVING PARTY DA	TA				
Name:	JANSSEN R&D IRELAND				
Street Address:	EASTGATE VILLAGE, EASTGATE, LITTLE ISLAND				
City:	CO CORK				
State/Country:	IRELAND				
PROPERTY NUMBERS	Total: 2				
Property Type		Number			
Application Number:		15180603			
Application Number:		15972840			
CORRESPONDENCE D	ΑΤΑ				
		(617)832-7000			
		) the e-mail address first; if that l; if that is unsuccessful, it will k			
<b>-</b>		617-832-3572			
Email:		kmay@foleyhoag.com, patentdocketing@foleyhoag.com			
Correspondent Name:		FOLEY HOAG LLP			
		155 SEAPORT BOULEVARD			
Address Line 4:		BOSTON, MASSACHUSETTS 02	210-2600		
ATTORNEY DOCKET NUMBER:		PBH-00102 & PBH-00103	PBH-00102 & PBH-00103		
NAME OF SUBMITTER:		KAREN MAY	KAREN MAY		
SIGNATURE:		/Karen May/	/Karen May/		
DATE SIGNED:		05/24/2018			

## **General Assignment**

WHEREAS, Janssen Infectious Diseases BVBA having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

\*PolyInosinic-PolyCytidylic acid (Poly (I:C)) formulations for the treatment of upper respiratory tract infections"

for which on the 3<sup>rd</sup> day of May 2012, European Patent Application no. EP 12166595.4 was filed at the European Patent Office.

WHEREAS, Janssen R&D Ireland, having its place of business at Eastgate Village, Eastgate, Little Island, Co Cork, Ireland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assigner hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and relissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assigner.

The Assignor agrees that this general assignment is effective from the 3rd day of May 2012.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Infectious Diseases BV8A

Jutas

Luc Quaghebeur, Proxy holder For Janssen Infectious Diseases BVBA

For Janssen R&D Ireland

Frank Daelemans, Proxy holder For Janssen R&D Ireland

RECORDED: 11/03/2014 RECORDED: 05/25/2018 PATENT REEL: 034**P9**ATT**EIN4**ME: 0698 REEL: 045904 FRAME: 0136